Company intelligence / Profile preview

PTS Diagnostics

Whitestown / Indianapolis, Indiana, United Statesptsdiagnostics.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company's point-of-care devices—CardioChek and A1CNow—are commercially available worldwide. CardioChek products have screened over 120 million patients globally. These devices provide rapid results for lipid panels and A1C to support cardiovascular and diabetes care at the point of care.

Therapeutic areas: CardiovascularEndocrinology
Modalities: DeviceNon-pharmacological therapy
Industry: Protein Biomarker Diagnostics

Partnerships

Avantor agreement for distribution/supply chain partnership as of October 2023

Beyond the preview

Go deeper on PTS Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTS Diagnostics.

Explore the full profile